Pfizer's COVID-19 vaccine sales forecast to continue growth

Pfizer (NYSE: PFE) has already reported eye-watering annual revenue of $100.3 billion for 2022 driven by its products related to the COVID-19 pandemic, notably the Comirnaty vaccine, which witnessed a record demand last year with forecast sales of $37 billion.

The vaccine, developed with Germany’s BioNTech (Nasdaq: BNTX), is expected to maintain the sales dominance it saw during the COVID-19 pandemic going into the future, with the average annual sales forecast rising by 19% between first- and second-half 2022, according to analytics firm GlobalData’s Coronavirus Disease 2019 (COVID-19) Sector Forecast: H2 2022 Global Analyst Consensus Sales Forecast report.

GlobalData pharma analyst Kevin Marcaida commented: “Comirnaty’s 2022 sales forecast is expected to rise by 8%, likely due to Pfizer winning a $3.2 billion agreement with the US government to supply 105 million doses for a fall vaccination campaign. The deal also offers the US the option to procure an additional 300 million doses, including a mix of doses for both adults and children, which could boost future sales if the option is used.”